drugset / Trial / NCT04685421

Liposomal Bupivacaine Pharmacokinetic Study After Median Sternotomy Incision Infiltration in a Pediatric Cardiac Surgery

NCT04685421 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the plasma concentration of bupivacaine at various time points after Exparel (bupivacaine liposome injectable suspension, Pacira Pharmaceuticals, Inc., Parsippany, NJ) is injected subcutaneously for median sternotomy incisions in pediatric cardiac surgery patients.

Timeline

Start
2021-07-15
Primary completion
2023-06-01
Completion
2023-06-01

Outcome

Outcome not reported

Stopped: “PI, Christopher Tirotta, no longer at NCH as of 5-26-23.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified — Subcutaneous

Indications